Trial intelligence / Profile preview

Docetaxel plus cisplatin induction chemotherapy followed by concurrent chemoradiotherapy vs concurrent chemoradiotherapy in locally localized nasopharyngeal carcinoma

ChiCTR-IPR-17011605Phase 4Recruiting

Sponsor
Xiangya Hospital, Central South University
Start
Jun 2017
Modality
Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, randomised trial of docetaxel and cisplatin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Progression-free survival. Started Jun 2017; status: recruiting.

02

Drugs

docetaxelcisplatin
03

Conditions

nasopharyngeal carcinoma (NPC)

Beyond the preview

Go deeper on ChiCTR-IPR-17011605.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR-IPR-17011605.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call